Search

Your search keyword '"Karzai, Fatima"' showing total 357 results
Start Over Author "Karzai, Fatima"
357 results on '"Karzai, Fatima"'

1. Castration Levels of Testosterone Results in Atrophy of Androgen-sensitive Perineal Muscles: A Potential Biomarker for Male Hypogonadism

Author

Rathi, Nityam, Blake, Zoë, Hyman, Jason, Nemirovsky, Daniel R., Gelikman, David G., Hesswani, Charles, Koller, Christopher, Nethala, Daniel, Mendhiratta, Neil, Kenigsberg, Alexander P., Noun, Jibriel, Dahut, William, Karzai, Fatima Y., Linehan, W. Marston, Pinto, Peter A., Turkbey, Baris, and Gurram, Sandeep

Published
2025
Full Text
View/download PDF

2. Quantitative Analysis of Serial Positron Emission Tomography Imaging in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide

Author

Gandhy, Shruti U., Karzai, Fatima H., Bilusic, Marijo, McMahon, Sheri, Cordes, Lisa M., Marte, Jennifer, Weisman, Amy J., Perk, Timothy G., Lindenberg, Liza, Mena, Esther, Turkbey, Baris, Arlen, Philip M., Dahut, William L., Figg, William D., Choyke, Peter, Gulley, James L., and Madan, Ravi A.

Published
2024
Full Text
View/download PDF

5. Accelerating precision medicine in metastatic prostate cancer

Author

Mateo, Joaquin, McKay, Rana, Abida, Wassim, Aggarwal, Rahul, Alumkal, Joshi, Alva, Ajjai, Feng, Felix, Gao, Xin, Graff, Julie, Hussain, Maha, Karzai, Fatima, Montgomery, Bruce, Oh, William, Patel, Vaibhav, Rathkopf, Dana, Rettig, Matthew, Schultz, Nikolaus, Smith, Matthew, Solit, David, Sternberg, Cora, Van Allen, Eliezer, VanderWeele, David, Vinson, Jake, Soule, Howard R, Chinnaiyan, Arul, Small, Eric, Simons, Jonathan W, Dahut, William, Miyahira, Andrea K, and Beltran, Himisha

Subjects
Clinical Research, Human Genome, Genetics, Cancer, Biotechnology, Urologic Diseases, Aging, Health Services, Prostate Cancer, Good Health and Well Being, Early Detection of Cancer, Humans, Male, Medical Oncology, Precision Medicine, Prostate-Specific Antigen, Prostatic Neoplasms
Abstract

Despite advances in prostate cancer screening and treatment, available therapy options, particularly in later stages of the disease, remain limited and the treatment-resistant setting represents a serious unmet medical need. Moreover, disease heterogeneity and disparities in patient access to medical advances result in significant variability in outcomes across patients. Disease classification based on genomic sequencing is a promising approach to identify patients whose tumors exhibit actionable targets and make more informed treatment decisions. Here we discuss how we can accelerate precision oncology to inform broader genomically-driven clinical decisions for men with advanced prostate cancer, drug development and ultimately contribute to new treatment paradigms.

Published
2020

6. Clinically oriented prediction of patient response to targeted and immunotherapies from the tumor transcriptome

Author

Dinstag, Gal, Shulman, Eldad D., Elis, Efrat, Ben-Zvi, Doreen S., Tirosh, Omer, Maimon, Eden, Meilijson, Isaac, Elalouf, Emmanuel, Temkin, Boris, Vitkovsky, Philipp, Schiff, Eyal, Hoang, Danh-Tai, Sinha, Sanju, Nair, Nishanth Ulhas, Lee, Joo Sang, Schäffer, Alejandro A., Ronai, Ze’ev, Juric, Dejan, Apolo, Andrea B., Dahut, William L., Lipkowitz, Stanley, Berger, Raanan, Kurzrock, Razelle, Papanicolau-Sengos, Antonios, Karzai, Fatima, Gilbert, Mark R., Aldape, Kenneth, Rajagopal, Padma S., Beker, Tuvik, Ruppin, Eytan, and Aharonov, Ranit

Published
2023
Full Text
View/download PDF

7. Prospective monitoring of prostate specific membrane antigen (PSMA) –positive recurrent prostate cancer: Preliminary data from 6 months PSMA follow-up.

Author

Madan, Ravi Amrit, Abel, Melissa Lauren, Mena, Esther, Lindenberg, Liza, Hausler, Megan, Williams, Monique, Hankin, Amy, Aragon-Ching, Jeanny B., Sena, Laura, Pachynski, Russell Kent, Posadas, Edwin Melencio, Moon, Helen, Bilusic, Marijo, Arlen, Philip M., Patel, Krishnan R., Jolissaint, Deborah, Chesnut, Gregory T, Figg, William Douglas, Karzai, Fatima, and Choyke, Peter L.

Published
2025
Full Text
View/download PDF

8. Association of localized high-risk prostate cancer (PC) and an androgen receptor low subpopulation susceptible to HER2 inhibition.

Author

Sowalsky, Adam G., Wilkinson, Scott C., Ku, Anson T., Lis, Rosina T., King, Isaiah M., Low, Daniel, Trostel, Shana Y., Baj, Anna, Kartal, Sumeyra, Heyward, Kayla, Vo, Baohan Thi, Jansen, Caroline Stewart, Ye, Huihui, Harmon, Stephanie A., Kissick, Haydn T., Pinto, Peter A., Choyke, Peter L., Turkbey, Baris, Dahut, William L., and Karzai, Fatima

Published
2025
Full Text
View/download PDF

10. Radium 223 without androgen deprivation therapy (ADT) in patients (Pts) with biochemically recurrent prostate cancer (BCR) and PET findings in the bones.

Author

Abel, Melissa Lauren, Karzai, Fatima, Arlen, Philip M., Chen, Clara, Mena, Esther, Lindenberg, Liza, Aragon-Ching, Jeanny B., Cordes, Lisa M., Lee-Wisdom, Katherine, Hankin, Amy, Williams, Monique, McKinney, Yolanda L, Gulley, James L, Figg, William Douglas, Choyke, Peter, and Madan, Ravi Amrit

Published
2025
Full Text
View/download PDF

12. Willingness of patients with biochemically recurrent prostate cancer (BCR) with positive 18F-dcfpyl PET/CT PSMA to monitor without treatment.

Author

Williams, Monique, primary, Hankin, Amy, additional, Hausler, Megan, additional, Mena Gonzalez, Esther, additional, Lindenberg, Liza, additional, Aragon-Ching, Jeanny B., additional, Sena, Laura, additional, Arlen, Philip M., additional, Karzai, Fatima, additional, Choyke, Peter L, additional, and Madan, Ravi Amrit, additional

Published
2024
Full Text
View/download PDF

14. Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy

Author

Wilkinson, Scott, Ye, Huihui, Karzai, Fatima, Harmon, Stephanie A., Terrigino, Nicholas T., VanderWeele, David J., Bright, John R., Atway, Rayann, Trostel, Shana Y., Carrabba, Nicole V., Whitlock, Nichelle C., Walker, Stephanie M., Lis, Rosina T., Abdul Sater, Houssein, Capaldo, Brian J., Madan, Ravi A., Gulley, James L., Chun, Guinevere, Merino, Maria J., Pinto, Peter A., Salles, Daniela C., Kaur, Harsimar B., Lotan, Tamara L., Venzon, David J., Choyke, Peter L., Turkbey, Baris, Dahut, William L., and Sowalsky, Adam G.

Published
2021
Full Text
View/download PDF

17. MP18-09 MORE THAN MEETS THE EYE: EVALUATING THE EFFECT OF NOVEL NEOADJUVANT ANDROGEN SIGNALING INHIBITION ON PROSTATE MULTIPARAMETRIC MRI

Author

Koller, Christopher R., primary, Parikh, Sahil H., additional, Schuppe, Kyle C., additional, Hesswani, Charles, additional, Azar, William S., additional, Kenigsberg, Alexander P., additional, Gelikman, David G., additional, Mendhiratta, Neil, additional, Azari, Sarah, additional, Nethala, Daniel, additional, Gold, Samuel, additional, Gurram, Sandeep, additional, Madan, Ravi A., additional, Karzai, Fatima, additional, Turkbey, Baris, additional, and Pinto, Peter A., additional

Published
2024
Full Text
View/download PDF

18. Stem cell dynamics and cellular heterogeneity across lineage subtypes of castrate resistant prostate cancer

Author

Beshiri, Michael L, primary, Capaldo, Brian J, additional, Lake, Ross, additional, Ku, Anson T, additional, Burner, Danielle, additional, Tice, Caitlin M, additional, Tran, Crystal, additional, Kostas, Julianna, additional, Alilin, Aian Neil, additional, Yin, Juan Juan, additional, Agarwal, Supreet, additional, Morris, Samantha A, additional, Karzai, Fatima H, additional, Lotan, Tamara L, additional, Dahut, William L, additional, Sowalsky, Adam G, additional, and Kelly, Kathleen, additional

Published
2024
Full Text
View/download PDF

21. Deciphering the enigma of neuroendocrine prostate Cancer

Author

Karzai, Fatima and Madan, Ravi A.

Abstract

Diagnosing neuroendocrine prostate cancer The last two decades have seen a remarkable expansion of therapeutic options that improve survival for men with metastatic prostate cancer, yet, for most patients, these [...], Despite the clinical advances in managing metastatic prostate cancer in the last 20 years, treatments for patients with metastatic disease only offer a brief respite from disease progression, especially after first-line therapies. Research into treatment resistance has defined a subset of patients with neuroendocrine differentiation of their prostate adenocarcinoma. Although neuroendocrine findings in conjunction with prostate adenocarcinoma can be seen in pathology samples at all stages of disease, the neuroendocrine variant of prostate cancer associated with poor outcomes occurs in approximately 20% of men with advanced disease. In this issue of JCI, Zhao, Sperger, and colleagues present data for a promising biomarker platform that can detect neuroendocrine prostate cancer after serial sampling of patients' blood with a high degree of sensitivity and specificity. This assay will be tested in several current and future trials to better define its potential clinical role and perhaps provide a greater understanding of neuroendocrine prostate cancer itself.

Published
2022
Full Text
View/download PDF

23. Abstract PR005: Tracing the clonal dynamic of metastatic castration-resistant prostate cancer over immunotherapy using circulating tumor DNA

Author

Li, Chennan, primary, Baj, Anna, additional, Seo, Clara C. Y., additional, Terrigino, Nicholas T., additional, Bright, John R., additional, Hennigan, S. Thomas, additional, King, Isaiah M., additional, Wilkinson, Scott, additional, Trostel, Shana Y., additional, Figg, William D., additional, Dahut, William L., additional, Lee, Jung Min, additional, Takeda, David Y., additional, Karzai, Fatima, additional, and Sowalsky, Adam G., additional

Published
2024
Full Text
View/download PDF

25. Increasing diversity in clinical trials: demographic trends at the National Cancer Institute, 2005-2020.

Author

Choradia, Nirmal, Karzai, Fatima, Nipp, Ryan, Naqash, Abdul Rafeh, Gulley, James L, and Floudas, Charalampos S

Subjects
*CLINICAL trials, *AFRICAN Americans, *PACIFIC Islanders, *ALASKA Natives, *OLDER people
Abstract

Background We described participant demographics for National Cancer Institute (NCI) clinical trials at the clinical center (NCI-CC participants) of the National Institutes of Health to identify enrollment disparities. Methods We analyzed NCI-CC data from 2005 to 2020, calculated enrollment fractions, compared with the US cancer population represented by the Surveillance, Epidemiology, and End Results cancer incidence data (2018) and the Cancer in North America database (2018), and compared further with clinical trial disparities data from the NCI Community Oncology Research Program and National Clinical Trials Network (2005-2019), and from ClinicalTrials.gov (2003-2016). Results NCI-CC (38 531 participants) had higher enrollment fractions for older adults (8.5%), male (5.6%), non-Hispanic (5.1%), and Black or African American (5.3%) participants; lower women proportion across race and ethnicity; and fewer female sex-specific cancer (6.8%) than male sex-specific cancer (11.7%) participants. NCI-CC had lower median age than Surveillance, Epidemiology, and End Results (54.0 vs 65.4); more Black or African American participants (12.0% vs 11.1%); and fewer women (41.7% vs 49.5%), White (76.1% vs 80.5%), Asian or Pacific Islander (4.6% vs 6.0%), American Indian or Alaska Native (0.3% vs 0.5%), and Hispanic participants (7.1% vs 13%). NCI-CC had more Black or African American and Asian or Pacific Islander participants; fewer Hispanic participants than the NCI Community Oncology Research Program and National Clinical Trials Network; more Black or African American and Hispanic participants; fewer Asian or Pacific Islander participants than ClinicalTrials.gov data. Improvement was noted for NCI-CC (older adults, Black or African American, Asian or Pacific Islander, Hispanic participants). Conclusion We found lower representation of older adults, women, Asian or Pacific Islander, American Indian or Alaska Native, and Hispanic participants vs the US cancer population and higher representation of Black or African American vs US cancer population and oncology clinical trials. Multifaceted efforts are underway to reduce disparities in cancer clinical trials at the NCI-CC. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

26. 587 Nivolumab increased vaccine induced T-cell infiltration in Prostate cancer

Author

Lassoued, Wiem, primary, Burnett, Daniel, additional, Canubas, Kenneth, additional, Bailey, Shania, additional, Marte, Jennifer, additional, William, Nikki, additional, Hankin, Amy, additional, Manukyan, Manuk, additional, Manu, Michell, additional, Dahut, William, additional, Pinto, Peter, additional, Karzai, Fatima, additional, Madan, Ravi, additional, Sater, Houssein Abdul, additional, and Gulley, James L, additional

Published
2023
Full Text
View/download PDF

29. Quantitative Analysis of Serial Positron Emission Tomography Imaging in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide

Author

Gandhy, Shruti U., primary, Karzai, Fatima H., additional, Bilusic, Marijo, additional, McMahon, Sheri, additional, Cordes, Lisa M., additional, Marte, Jennifer, additional, Weisman, Amy J., additional, Perk, Timothy G., additional, Lindenberg, Liza, additional, Mena, Esther, additional, Turkbey, Baris, additional, Arlen, Philip M., additional, Dahut, William L., additional, Figg, William D., additional, Choyke, Peter, additional, Gulley, James L., additional, and Madan, Ravi A., additional

Published
2023
Full Text
View/download PDF

31. Large Cell Neuroendocrine Prostate Cancer: Large Is Not Small.

Author

Serritella, Anthony V, Beltran, Himisha, Lotan, Tamara L, VanderWeele, David J, Karzai, Fatima, Madan, Ravi A, and Hussain, Maha

Subjects
THERAPEUTIC use of antineoplastic agents, IMMUNOHISTOCHEMISTRY, CABAZITAXEL, PLATINUM, HYDROCARBONS, NEUROENDOCRINE tumors, PROSTATE-specific antigen, PROSTATE tumors, PHENOTYPES
Abstract

The article comments on the difference of large cell neuroendocrine prostate cancer (LCPC) from small-cell neuroendocrine carcinoma (SCPC) ). It clarifies that neuroendocrine differentiation does not imply small cell or large cell carcinoma. It offers treatment recommendations for LCPC, a guide for histologic diagnosis of SCPC and LCPC, and recommendations for immunohistochemical diagnosis of SCPC and LCPC and for future investigation of LCPC.

Published
2024
Full Text
View/download PDF

32. A Phase II Clinical Trial of TRC105 (Anti-Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial Carcinoma

Author

Apolo, Andrea B., Karzai, Fatima H., Trepel, Jane B., Alarcon, Sylvia, Lee, Sunmin, Lee, Min-Jung, Tomita, Yusuke, Cao, Liang, Yu, Yunkai, Merino, Maria J., Madan, Ravi A., Parnes, Howard L., Steinberg, Seth M., Rodriguez, Beatriz Walter, Seon, Ben K., Gulley, James L., Arlen, Philip M., Dawson, Nancy A., Figg, William D., and Dahut, William L.

Published
2017
Full Text
View/download PDF

33. A case report of multiple primary prostate tumors with differential drug sensitivity

Author

Wilkinson, Scott, Harmon, Stephanie A., Terrigino, Nicholas T., Karzai, Fatima, Pinto, Peter A., Madan, Ravi A., VanderWeele, David J., Lake, Ross, Atway, Rayann, Bright, John R., Carrabba, Nicole V., Trostel, Shana Y., Lis, Rosina T., Chun, Guinevere, Gulley, James L., Merino, Maria J., Choyke, Peter L., Ye, Huihui, Dahut, William L., Turkbey, Baris, and Sowalsky, Adam G.

Published
2020
Full Text
View/download PDF

36. Flutamide With or Without PROSTVAC in Non-metastatic Castration Resistant (M0) Prostate Cancer

Author

Madan, Ravi A, primary, Bilusic, Marijo, additional, Stein, Mark N, additional, Donahue, Renee N, additional, Arlen, Philip M, additional, Karzai, Fatima, additional, Plimack, Elizabeth, additional, Wong, Yu-Ning, additional, Geynisman, Daniel M, additional, Zibelman, Matthew, additional, Mayer, Tina, additional, Strauss, Julius, additional, Chen, Gang, additional, Rauckhorst, Myrna, additional, McMahon, Sheri, additional, Couvillon, Anna, additional, Steinberg, Seth, additional, Figg, William D, additional, Dahut, William L, additional, Schlom, Jeffrey, additional, and Gulley, James L, additional

Published
2023
Full Text
View/download PDF

38. Abstract 957: Prediction of patient response to targeted and immunotherapies from the tumor transcriptome in a wide set of indications and clinical trials

Author

Dinstag, Gal, primary, Shulman, Eldad D., additional, Elis, Efrat, additional, Ben-Zvi, Doreen S., additional, Tirosh, Omer, additional, Maimon, Eden, additional, Meilijson, Isaac, additional, Elalouf, Emmanuel, additional, Temkin, Boris, additional, Vitkovsky, Philipp, additional, Schiff, Eyal, additional, Hoang, Danh-Tai, additional, Sinha, Sanju, additional, Nair, Nishanth Ulhas, additional, Sang-Lee, Joo, additional, Schäffer, Alejandro A., additional, Ronai, Ze'ev, additional, Juric, Dejan, additional, Apolo, Andrea B., additional, Dahut, William L., additional, Lipkowitz, Stanley, additional, Berger, Raanan, additional, Kurzrock, Razelle, additional, Papanicolau-Sengos, Antonios, additional, Karzai, Fatima, additional, Gilbert, Mark R., additional, Aldape, Kenneth, additional, Rajagopal, Padma S., additional, Beker, Tuvik, additional, Ruppin, Eytan, additional, and Aharonov, Ranit, additional

Published
2023
Full Text
View/download PDF

39. Supplementary Figure from Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer

Author

Sowalsky, Adam G., primary, Figueiredo, Ines, primary, Lis, Rosina T., primary, Coleman, Ilsa, primary, Gurel, Bora, primary, Bogdan, Denisa, primary, Yuan, Wei, primary, Russo, Joshua W., primary, Bright, John R., primary, Whitlock, Nichelle C., primary, Trostel, Shana Y., primary, Ku, Anson T., primary, Patel, Radhika A., primary, True, Lawrence D., primary, Welti, Jonathan, primary, Jimenez-Vacas, Juan M., primary, Rodrigues, Daniel Nava, primary, Riisnaes, Ruth, primary, Neeb, Antje, primary, Sprenger, Cynthia T., primary, Swain, Amanda, primary, Wilkinson, Scott, primary, Karzai, Fatima, primary, Dahut, William L., primary, Balk, Steven P., primary, Corey, Eva, primary, Nelson, Peter S., primary, Haffner, Michael C., primary, Plymate, Stephen R., primary, de Bono, Johann S., primary, and Sharp, Adam, primary

Published
2023
Full Text
View/download PDF

40. Supplementary Materials from A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic Screening

Author

Beshiri, Michael L., primary, Tice, Caitlin M., primary, Tran, Crystal, primary, Nguyen, Holly M., primary, Sowalsky, Adam G., primary, Agarwal, Supreet, primary, Jansson, Keith H., primary, Yang, Qi, primary, McGowen, Kerry M., primary, Yin, JuanJuan, primary, Alilin, Aian Neil, primary, Karzai, Fatima H., primary, Dahut, William L., primary, Corey, Eva, primary, and Kelly, Kathleen, primary

Published
2023
Full Text
View/download PDF

41. Supplementary Data from Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer

Author

Sowalsky, Adam G., primary, Figueiredo, Ines, primary, Lis, Rosina T., primary, Coleman, Ilsa, primary, Gurel, Bora, primary, Bogdan, Denisa, primary, Yuan, Wei, primary, Russo, Joshua W., primary, Bright, John R., primary, Whitlock, Nichelle C., primary, Trostel, Shana Y., primary, Ku, Anson T., primary, Patel, Radhika A., primary, True, Lawrence D., primary, Welti, Jonathan, primary, Jimenez-Vacas, Juan M., primary, Rodrigues, Daniel Nava, primary, Riisnaes, Ruth, primary, Neeb, Antje, primary, Sprenger, Cynthia T., primary, Swain, Amanda, primary, Wilkinson, Scott, primary, Karzai, Fatima, primary, Dahut, William L., primary, Balk, Steven P., primary, Corey, Eva, primary, Nelson, Peter S., primary, Haffner, Michael C., primary, Plymate, Stephen R., primary, de Bono, Johann S., primary, and Sharp, Adam, primary

Published
2023
Full Text
View/download PDF

42. Supplementary Figures from A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic Screening

Author

Beshiri, Michael L., primary, Tice, Caitlin M., primary, Tran, Crystal, primary, Nguyen, Holly M., primary, Sowalsky, Adam G., primary, Agarwal, Supreet, primary, Jansson, Keith H., primary, Yang, Qi, primary, McGowen, Kerry M., primary, Yin, JuanJuan, primary, Alilin, Aian Neil, primary, Karzai, Fatima H., primary, Dahut, William L., primary, Corey, Eva, primary, and Kelly, Kathleen, primary

Published
2023
Full Text
View/download PDF

43. Supplementary Tables from A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic Screening

Author

Beshiri, Michael L., primary, Tice, Caitlin M., primary, Tran, Crystal, primary, Nguyen, Holly M., primary, Sowalsky, Adam G., primary, Agarwal, Supreet, primary, Jansson, Keith H., primary, Yang, Qi, primary, McGowen, Kerry M., primary, Yin, JuanJuan, primary, Alilin, Aian Neil, primary, Karzai, Fatima H., primary, Dahut, William L., primary, Corey, Eva, primary, and Kelly, Kathleen, primary

Published
2023
Full Text
View/download PDF

44. Supplementary Table 4 from A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic Screening

Author

Beshiri, Michael L., primary, Tice, Caitlin M., primary, Tran, Crystal, primary, Nguyen, Holly M., primary, Sowalsky, Adam G., primary, Agarwal, Supreet, primary, Jansson, Keith H., primary, Yang, Qi, primary, McGowen, Kerry M., primary, Yin, JuanJuan, primary, Alilin, Aian Neil, primary, Karzai, Fatima H., primary, Dahut, William L., primary, Corey, Eva, primary, and Kelly, Kathleen, primary

Published
2023
Full Text
View/download PDF

45. First-line pembrolizumab plus androgen deprivation therapy for locally advanced microsatellite instability-high prostate cancer in a patient with Muir-Torre syndrome: A case report

Author

Atiq, Mohammad O., primary, Pastor, Danielle M., additional, Karzai, Fatima, additional, Hankin, Amy R., additional, Turkbey, Baris, additional, Cordes, Lisa M., additional, Brownell, Isaac, additional, Liu, Yi, additional, Chesnut, Gregory T., additional, and Madan, Ravi A., additional

Published
2023
Full Text
View/download PDF

47. Metformin for biochemical recurrence of prostate cancer: Immune data from a phase 2 study.

Author

Bilusic, Marijo, primary, Toney, NIcole J, additional, Donahue, Renee Nicole, additional, Karzai, Fatima, additional, Madan, Ravi Amrit, additional, Schlom, Jeffrey, additional, Gulley, James L., additional, Rai, Priyamvada, additional, Due, Cassie, additional, Gregory, Philip, additional, Mateo-Victoriano, Beatriz, additional, Plimack, Elizabeth R., additional, and Geynisman, Daniel M., additional

Published
2023
Full Text
View/download PDF

48. Inherited risk for prostate cancer (PCa): Following the natural history of men with high-risk genetics using multiparametric MRI (mpMRI).

Author

Couvillon, Anna, primary, Turkbey, Baris, additional, Choyke, Peter L., additional, Lee-Wisdom, Katherine, additional, McKinney, Yolanda, additional, Sidlow, Robert, additional, Mullane, Michael P., additional, Giri, Veda N., additional, Morgan, Todd Matthew, additional, Cheng, Heather H., additional, Merino, Maria J., additional, Figg, William Douglas, additional, Pinto, Peter A., additional, Dahut, William L., additional, and Karzai, Fatima, additional

Published
2023
Full Text
View/download PDF

49. Effects of docetaxel on circulating immune cell subsets and association with outcomes in metastatic castration-sensitive prostate cancer.

Author

Chandran, Elias, primary, Goswami, Meghali, additional, Donahue, Renee Nicole, additional, Atiq, Mohammad O., additional, Karzai, Fatima, additional, Bilusic, Marijo, additional, Marte, Jennifer L., additional, Arlen, Philip M., additional, Cordes, Lisa M., additional, Owens, Helen, additional, Hausler, Megan, additional, Hankin, Amy, additional, Williams, Monique, additional, Dahut, William L., additional, Figg, William Douglas, additional, Schlom, Jeffrey, additional, Gulley, James L., additional, and Madan, Ravi Amrit, additional

Published
2023
Full Text
View/download PDF

50. A Phase I Single-Arm Study of Biweekly NHS-IL12 in Patients With Metastatic Solid Tumors

Author

Gatti-Mays, Margaret E, primary, Tschernia, Nicholas P, additional, Strauss, Julius, additional, Madan, Ravi A, additional, Karzai, Fatima H, additional, Bilusic, Marijo, additional, Redman, Jason, additional, Sater, Houssein Abdul, additional, Floudas, Charalampos S, additional, Toney, Nicole J, additional, Donahue, Renee N, additional, Jochems, Caroline, additional, Marté, Jennifer L, additional, Francis, Deneise, additional, McMahon, Sheri, additional, Lamping, Elizabeth, additional, Cordes, Lisa, additional, Schlom, Jeffrey, additional, and Gulley, James L, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results